The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 947-958

  Schwartz, David L ^a   Powis, Garth ^a   Thitai Kumar, Arun ^a   He, Yi ^a   Bankson, James ^a   Williams, Ryan ^a   Lemos, Robert ^a   Oh, Junghwan ^a   Volgin, Andrei ^a   Soghomonyan, Suren ^a   Nishii, Ryuichi ^a   Alauddin, Mian ^a   Mukhopadhay, Uday ^a   Peng, Zhenghong ^a   Bornmann, William ^a   Gelovani, Juri ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; 5 ETHYL 2' FLUOROURACIL ARABINOSIDE; FLUORINE 18; GANCICLOVIR; HYPOXIA INDUCIBLE FACTOR 1; VASCULOTROPIN; 2 AMINO 3 (4' N,N BIS(2 CHLOROETHYL)AMINO)PHENYLPROPIONIC ACID N OXIDE; 2-AMINO-3-(4'-N,N-BIS(2-CHLOROETHYL)AMINO)PHENYLPROPIONIC ACID N-OXIDE; HIF1A PROTEIN, HUMAN; HIF1A PROTEIN, RAT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUSTARD GAS DERIVATIVE; PHENYLPROPIONIC ACID DERIVATIVE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CLONE; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION; RAT; REFRACTORY PERIOD; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT; TUMOR CELL; ULTRASOUND; XENOGRAFT; ADENOCARCINOMA; ANIMAL; CELL HYPOXIA; DRUG ANTAGONISM; DRUG SCREENING; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK TUMOR; METABOLISM; MOUSE; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; RADIATION EXPOSURE; STROMA CELL; TUMOR CELL CULTURE; WESTERN BLOTTING; WHOLE BODY RADIATION;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOMA; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; MUSTARD COMPOUNDS; PANCREATIC NEOPLASMS; PHENYLPROPIONATES; POSITRON-EMISSION TOMOGRAPHY; STROMAL CELLS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WHOLE-BODY IRRADIATION;

EID: 66449118481     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0981     Document Type: Article

References (30)

1. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943 (Pubitemid 26065381)
2. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer ofthe uterine cervix. Cancer Res 1996;56:4509-4515 (Pubitemid 26330463)
3. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000;57:39-43.
4. Quintiliani M. Modification of radiation sensitivity: the oxygen effect. Int J Radiat Oncol Biol Phys 1979;5:1069-1076 (Pubitemid 10191567)
5. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-1480 (Pubitemid 30217451)
6. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001;107:1-3.
7. Powis G, Kirkpatrick L. Hypoxia inducible factor-1α as a cancer drug target. Mol Cancer Ther 2004;3:647-654 (Pubitemid 39193744)
8. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732 (Pubitemid 37328811)
9. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-684 (Pubitemid 36749216)
10. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005;16:901-909 (Pubitemid 41416080)
11. Koh MY, Spivak-Kroizman T, Venturini S, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1β. Mol Cancer Ther 2008;7:90-100.
12. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol Cancer Ther 2004;3:233-244 (Pubitemid 39193698)
13. Jordan BF, Runquist M, Raghunand N, et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478. Neoplasia 2005;7:475-485 (Pubitemid 40796142)
14. Wen B, Burgman P, Zanzonico P, et al. A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging 2004;31:1530-1538 (Pubitemid 39592774)
15. Serganova I, Doubrovin M, Vider J, et al. Molecular imaging oftemporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 2004;64:6101-6108 (Pubitemid 39129410)
16. Alauddin MM, Conti PS, Fissekis JD. A general synthesis of [18F] labeled 2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyluracil nucleosides. J Labelled Comp Radiopharm 2003;46:285-289 (Pubitemid 36514050)
17. Nordsmark M, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-1075 (Pubitemid 32448504)
18. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-520 (Pubitemid 40799245)
19. Ceelen W, Smeets P, Backes W, et al. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. Int J Radiat Oncol Biol Phys 2006;64:1188-1196 (Pubitemid 43295316)
20. Kobayashi H, Reijnders K, English S, et al. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res 2004;10:7712-7720 (Pubitemid 39557536)
21. Crokart N, Jordan BF, Baudelet C, et al. Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys 2005;63:901-910 (Pubitemid 41400082)
22. Moeller BJ, Dreher MR, Rabbani ZN, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005;8:99-110. (Pubitemid 41132739)
23. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression oftumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000;6:1335-1340 (Pubitemid 32001016)
24. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-1159 (Pubitemid 36583102)
25. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001;293:293-297 (Pubitemid 32694744)
26. Guelinckx PJ, Boeckx WD, Fossion E, Gruwez JA. Scanning electron microscopy ofi rradiated recipient blood vessels in head and neck free flaps. Plast Reconstr Surg 1984;74:217-226 (Pubitemid 14053326)
27. 2- regulated gene expression. FASEB J 2002;16:1151-1162
28. Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in HEK293T cells. Cancer Res 2005;65:3299-3306 (Pubitemid 40524614)
29. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003;4:133-146 (Pubitemid 37040829)
30. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757. (Pubitemid 44832019)